Ubs Group Ag An2 Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 19,574 shares of ANTX stock, worth $42,084. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,574

Holding current value

$42,084

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.78 - $21.53 $54,415 - $421,428	19,574 New	19,574 $63,000
Q3 2023 Nov 09, 2023	SELL	$7.58 - $16.08 $65,392 - $138,722	-8,627 Reduced 17.37%	41,046 $660,000
Q2 2023 Aug 11, 2023	SELL	$5.06 - $9.91 $12,913 - $25,290	-2,552 Reduced 4.89%	49,673 $422,000
Q1 2023 May 12, 2023	BUY	$7.94 - $15.6 $6,113 - $12,012	770 Added 1.5%	52,225 $515,000
Q4 2022 Feb 08, 2023	BUY	$8.51 - $16.78 $190,181 - $374,999	22,348 Added 76.78%	51,455 $490,000

Q3 2022 Nov 10, 2022	SELL	$7.61 - $22.29 $146,568 - $429,305	-19,260 Reduced 39.82%	29,107 $506,000
Q2 2022 Aug 10, 2022	BUY	$7.7 - $18.82 $363,509 - $888,473	47,209 Added 4076.77%	48,367 $375,000
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $17,370 - $17,833	1,158 New	1,158 $17,000

Others Institutions Holding ANTX

# of Institutions

Shares Held

13.2M

Call Options Held

Put Options Held

Ken Griffin Citadel Advisors LLC | Chicago, Il

1.56M
Shares

$3.35 Million
0.0% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

1.56M
Shares

$3.34 Million
0.53% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

1.39M
Shares

$2.99 Million
0.24% of portfolio
Bvf Inc San Francisco, CA

1.24M
Shares

$2.66 Million
0.12% of portfolio
Janus Henderson Group PLC London, X0

1.22M
Shares

$2.63 Million
0.0% of portfolio

View Full List

About AN2 Therapeutics, Inc.

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $41.7M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

More about ANTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account